Artelo Biosciences (ARTL) Corporate presentation summary

Strategic focus and pipeline

• Advancing a platform of lipid signaling modulation drug candidates targeting pain, cancer, anxiety, depression, and other conditions.

• Lead programs include ART27.13 (dual cannabinoid receptor agonist), ART26.12 (FABP5 inhibitor), and ART12.11 (CBD:TMP cocrystal).

• Near-term clinical catalysts expected within 12–18 months for all three programs.

• Targeting billion-dollar markets such as cancer anorexia, CIPN, anxiety, and psoriasis.

• Robust patent estate with 38 issued and 51 pending patents, supporting global exclusivity.

ART27.13: Cancer anorexia/cachexia

• Addresses significant unmet need in cancer anorexia/cachexia syndrome, affecting up to 80% of advanced cancer patients.

• Demonstrated dose-dependent weight gain and muscle preservation in preclinical and Phase 1 studies.

• CARES Phase 1/2 trials showed weight stabilization/gain and increased activity versus placebo, with a favorable safety profile up to 1300 μg.

• Most common adverse events were mild, including somnolence and dry mouth; no fatal or serious drug-related events.

• Phase 2 interim data confirmed efficacy in weight gain and activity improvement.

ART26.12: FABP5 inhibitor for neuropathy and cancer

• Lead indication is chemotherapy-induced peripheral neuropathy (CIPN), a major unmet need with no FDA-approved therapies.

• Preclinical studies showed significant reversal of neuropathic pain in animal models.

• Phase 1 SAD/FE study in healthy volunteers demonstrated excellent safety, predictable pharmacokinetics, and a wide therapeutic window.

• Potential for both fed and fasted dosing, supporting flexible clinical development.

• Platform has broad potential in anxiety, depression, cancer, pain, and dermatology.